| Overview |
| bs-15573R-Cy3 |
| IGHD Polyclonal Antibody, Cy3 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human IGHD |
| 51-150/384 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| Secreted, Cell membrane |
| IGHD; Constant region of heavy chain of IgD; Ig delta chain C region; Ig delta chain C region secreted form; IgD; Igh-5; Immunoglobulin delta; Immunoglobulin heavy constant delta; IGHD_HUMAN; Immunoglobulin heavy delta chain. |
| Ig delta chain C region is an allelic product of the human IGHD gene. The two known IGHD alleles, IGHD*01 and IGHD*02, respectively produce isoforms 1, a secreted protein, and 2, a single-pass type I membrane protein. A member of the adaptive immune system, IgD are monomers expressed by activated B cells. Containing 3 Ig-like (immunoglobulin-like) domains, IgD chain C is located on chromosome 14 within the human heavy chain locus, lying on the 3? side of the IgM chain C region from the V-D-J cassette. Polyadenylation at certain sites along the heavy chain locus likely effects the mechanism that determines the alternative splicing event which results in the expression of either IgD chain C or IgM chain C. Some studies have suggested that antigenic coactivation of IgD+ B cells can have a negative influence on bone resorption during infectious events. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz